Takeda Pharmaceutical - Implantable Cell Chamber Device, EP4120958A1
Summary
The European Patent Office granted Takeda Pharmaceutical Company Limited Patent EP4120958A1 titled 'Implantable Cell Chamber Device and Uses Thereof,' published April 15, 2026. The patent application (filed by inventors LING, Vincent, IMAICHI, Sachiko, PHANEUF, Matthew, LONG, Nathaniel, KASSAB, Rayan, and ROBERTSON, Robbie James) covers technology related to implantable cell chamber devices and their therapeutic applications, with IPC classifications spanning prosthetics (A61F), biomedical materials (A61L), and therapeutic agents (A61P) including gastrointestinal applications. The patent is designated across 31 European member states including Germany, France, the United Kingdom, Italy, Spain, the Netherlands, Belgium, Austria, and Switzerland.
About this source
GovPing monitors EPO Patent Bulletin - Prosthetics (A61F) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 14 changes logged to date.
What changed
The European Patent Office granted Takeda Pharmaceutical Company Limited Patent EP4120958A1 titled 'Implantable Cell Chamber Device and Uses Thereof' on April 15, 2026. The patent covers implantable cell chamber device technology and its therapeutic applications, with IPC classifications spanning prosthetic devices (A61F 2/02), biomedical materials (A61L 27/18, 27/38, 27/50, 27/54, 27/56), and therapeutic agents including gastrointestinal applications (A61P 1/04). The patent is designated across 31 European member states including Germany, France, the United Kingdom, Italy, Spain, and other EPO member countries.
Takeda Pharmaceutical now holds enforceable patent rights in all designated EPO member states for a 20-year period from the application's filing date, providing exclusivity over the manufacture, use, and commercialisation of the claimed implantable cell chamber device technology. Competitors developing similar cell chamber implant devices should conduct freedom-to-operate analyses in the designated territories to assess potential infringement exposure.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
IMPLANTABLE CELL CHAMBER DEVICE AND USES THEREOF
Publication EP4120958A1 Kind: A1 Apr 15, 2026
Applicants
Takeda Pharmaceutical Company Limited
Inventors
LING, Vincent, IMAICHI, Sachiko, PHANEUF, Matthew, LONG, Nathaniel, KASSAB, Rayan, ROBERTSON, Robbie James
IPC Classifications
A61F 2/02 20060101AFI20240429BHEP A61L 27/18 20060101ALI20240429BHEP A61L 27/38 20060101ALI20240429BHEP A61L 27/50 20060101ALI20240429BHEP A61L 27/54 20060101ALI20240429BHEP A61L 27/56 20060101ALI20240429BHEP A61P 1/04 20060101ALI20240429BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Prosthetics (A61F)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Prosthetics (A61F) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.